Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of the National Cancer Institute

• Publication date

  2002-07-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JNCI/94.13.990PMID 12096084
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gene-expression profiles in hereditary breast cancer.

  2001cited by this paper
• Frequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer.

  2001cited by this paper
• Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.

  2001influential reference
• Coordinately up-regulated genes in ovarian cancer.

  2001cited by this paper
• Genetic factors in ovarian carcinoma

  2001cited by this paper
• Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes.

  2001cited by this paper
• Gene-expression profiles in hereditary breast cancer.

  2001cited by this paper
• Invariant chain expression in gastric cancer.

  2001cited by this paper
• In search of the tumour-suppressor functions of BRCA1 and BRCA2

  2000cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

  2000cited by this paper
• Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.

  2000cited by this paper
• BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.

  2000cited by this paper
• BRCA1 Effects on the Cell Cycle and the DNA Damage Response Are Linked to Altered Gene Expression*

  2000cited by this paper
• Expression of secreted frizzled related proteins 3 and 4 in human ventricular myocardium correlates with apoptosis related gene expression.

  2000cited by this paper
• Regulation of double-strand break-induced mammalian homologous recombination by UBL1, a RAD51-interacting protein.

  2000cited by this paper
• Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer.

  2000cited by this paper
• Lessons learned from BRCA1 and BRCA2

  2000cited by this paper
• Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer.

  2000cited by this paper
• Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors1

  2000cited by this paper
• Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

  2000influential reference
• Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

  2000cited by this paper
• Insights into the functions of BRCA1 and BRCA2.

  2000cited by this paper
• FrzB-2: a human secreted frizzled-related protein with a potential role in chondrocyte apoptosis.

  2000cited by this paper
• BRCA1 and E-cadherin promoter hypermethylation and gene inactivation in cancer-association or mechanism?

  2000cited by this paper
• Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

  1999cited by this paper
• Differential expression of frpHE: a novel human stromal protein of the secreted frizzled gene family, during the endometrial cycle and malignancy.

  1999cited by this paper
• Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.

  1999cited by this paper
• Invariant chain expression in colon neoplasms

  1999cited by this paper
• Class II transactivator: is it a master switch for MHC class II gene expression?

  1999cited by this paper
• Ovarian differentiation and gonadal failure.

  1999cited by this paper
• Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours

  1999cited by this paper
• Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray.

  1999cited by this paper
• Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas.

  1999cited by this paper
• Cluster analysis and display of genome-wide expression patterns.

  1998cited by this paper
• Frequency of germline and somatic BRCA1 mutations in ovarian cancer.

  1998cited by this paper
• Evidence for a Turner syndrome locus or loci at Xp11.2-p22.1.

  1998cited by this paper
• Identification of homo- and heteromeric interactions between members of the breast carcinoma-associated D52 protein family using the yeast two-hybrid system

  1998cited by this paper
• Class II transactivator-independent endothelial cell MHC class II gene activation induced by lymphocyte adhesion.

  1998cited by this paper
• Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.

  1998cited by this paper
• Radiation-enhanced expression of interferon-inducible genes in the KG1a primitive hematopoietic cell line

  1997cited by this paper
• A cytokine profile of normal and malignant ovary.

  1996cited by this paper
• Somatic mutations in the BRCA1 gene in sporadic ovarian tumours

  1995cited by this paper
• Molecular analysis of the topoisomerase II α gene and its expression in human ovarian cancer

  1994cited by this paper
• Molecular analysis of the topoisomerase II alpha gene and its expression in human ovarian cancer.

  1994cited by this paper
• P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.

  1991cited by this paper
• Amplified RNA synthesized from limited quantities of heterogeneous cDNA.

  1990cited by this paper

• Nuclear destabilisation – a possible genesis of cancer?

  2025cites this paper
• Exploiting RIG-I-like receptor pathway for cancer immunotherapy

  2023cites this paper
• BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy.

  2022cites this paper
• Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations

  2022cites this paper
• Prediction of homologous recombination deficiency from cancer gene expression data

  2022cites this paper
• Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers

  2022cites this paper
• Identification of key gene signatures for the overall survival of ovarian cancer

  2022cites this paper
• Increased gene expression variability in BRCA1-associated and basal-like breast tumours

  2021cites this paper
• Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer

  2021cites this paper
• Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes

  2021cites this paper
• The transcriptomic revolution and radiation biology

  2021cites this paper
• Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma

  2021cites this paper
• Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers

  2021influential citation
• Targeting progesterone signaling prevents metastatic ovarian cancer

  2020cites this paper
• Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours

  2020influential citation
• Germline PALB2 Mutations in Cancers and Its Distinction From Somatic PALB2 Mutations in Breast Cancers

  2020cites this paper
• Oncologic manifestations of Klinefelter syndrome

  2020cites this paper
• Homologous recombination-deficient cancers: approaches to improve treatment and patient selection

  2020cites this paper
• Ovarian Cancer Dissemination—A Cell Biologist’s Perspective

  2019cites this paper
• High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients

  2019cites this paper
• The Ambivalent Role of lncRNA Xist in Carcinogenesis

  2019cites this paper
• Implications of Long Noncoding RNAs in Cancer Epigenetics

  2018cites this paper
• Multi‐omics in high‐grade serous ovarian cancer: Biomarkers from genome to the immunome

  2018cites this paper
• PARP1 depletion induces RIG-I-dependent signaling in human cancer cells

  2018cites this paper
• Increased centrosome number in BRCA‐related breast cancer specimens determined by immunofluorescence analysis

  2018cites this paper
• Alteration of Epigenetic Regulation by Long Noncoding RNAs in Cancer

  2018cites this paper
• 1 PARP INHIBITORS AS P-GLYOPROTEIN SUBSTRATES

  2018cites this paper
• Ovarian Cancer Genetics: Subtypes and Risk Factors

  2018cites this paper
• Biomarkers for Homologous Recombination Deficiency in Cancer

  2018cites this paper
• A novel ensemble method for high-dimensional genomic data classification

  2018cites this paper
• Next generation sequencing-based emerging trends in molecular biology of gastric cancer.

  2018cites this paper
• BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFκB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells12

  2018cites this paper
• Development of PARP inhibitors in gynecological malignancies.

  2017cites this paper
• University of Groningen Therapeutic targeting and patient selection for cancers with homologous recombination defects

  2017cites this paper
• HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

  2017cites this paper
• Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer

  2017cites this paper
• Therapeutic targeting and patient selection for cancers with homologous recombination defects

  2017cites this paper
• Identification of licofelone through three-dimensional cell culture drug screening as a repurposed agent able to reverse drug resistant and cancer stem cell-like subpopulations in ovarian cancer

  2017cites this paper
• Epigenetic and LncRNA-Mediated Regulation of X Chromosome Inactivation and Its Impact on Pathogenesis

  2017cites this paper
• HRDetect : A mutational signature based predictor of BRCA 1 and BRCA 2 deficiency

  2017cites this paper
• Fuzzy inheritance: A novel form of somatic cell inheritance that regulates cell population heterogeneity

  2016cites this paper
• BRCAness revisited

  2016cites this paper
• Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients

  2016cites this paper
• Precursors of High-Grade Serous Carcinoma

  2016cites this paper
• The Open University ’ s repository of research publications and other research outputs Stacked regression ensemble for cancer class prediction Conference Item

  2016cites this paper
• Exploiting synthetic lethality in ovarian cancer

  2016cites this paper
• Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.

  2016cites this paper
• Gene Expression Profiling in Hereditary , BRCA 1-linked Breast Cancer : Preliminary Report

  2015cites this paper
• Interferons and the Immunogenic Effects of Cancer Therapy.

  2015cites this paper
• DNA Repair and Chemotherapy

  2015cites this paper
• Integrated analysis of gene expression profile and genetic variations associated with ovarian cancer.

  2015cites this paper
• Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk‐reducing salpingo‐oophorectomies

  2015cites this paper
• Study of the influence of the ph of water in the initiation of digestive tract injury in cadmium poisoning in rats

  2015cites this paper
• The molecular and genetic basis of inherited cancer risk in gynaecology

  2015cites this paper
• The Immune System and Response to Conventional Genotoxic Therapy

  2015cites this paper
• CONSEQUENCES OF BRCA1 EPIGENETIC SILENCING ON HOMOLOGOUS RECOMBINATION AND DISEASE PROGRESSION IN MYELOID NEOPLASMS

  2015cites this paper
• BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility – A proteomics study

  2015cites this paper
• Correlation between gene expression and mutator phenotype predicts homologous recombination deficiency and outcome in ovarian cancer

  2014cites this paper
• BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma—an Indian study

  2014influential citation
• T ECHNICAL I NFORMATION A PPLICATION I NFORMATION

  2014cites this paper
• Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.

  2014cites this paper
• Transcriptome profiling of the cancer and normal tissues from gastric cancer patients by deep sequencing

  2014cites this paper
• Ovarian cancer evolution through stochastic genome alterations: defining the genomic role in ovarian cancer

  2014cites this paper
• PARP Inhibitors as P-glyoprotein Substrates.

  2014cites this paper
• Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.

  2014cites this paper
• Up‐regulation of the interferon‐related genes in BRCA2 knockout epithelial cells

  2014cites this paper
• Molecular Pathology of Ovarian Cancer

  2013cites this paper
• Early Telomere Shortening and Genomic Instability in Tubo-Ovarian Preneoplastic Lesions

  2013cites this paper
• Cancer Genomics

  2013cites this paper
• Common genetic variants in the 9p21 region and their associations with multiple tumours

  2013cites this paper
• MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients

  2013cites this paper
• The contribution of recurrent BRCA2 mutations in unselected French Canadian ovarian cancer cases

  2013cites this paper
• Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.

  2013cites this paper
• Non-equivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations

  2013influential citation
• A combined multidimensional scaling and hierarchical clustering view for the exploratory analysis of multidimensional data

  2013cites this paper
• Heterochromatin instability in cancer: from the Barr body to satellites and the nuclear periphery.

  2013cites this paper
• Genomic Landscape of Ovarian Cancer

  2013cites this paper
• BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study

  2013cites this paper
• Deubiquitylating Enzymes and DNA Damage Response Pathways

  2013cites this paper
• BRCA Mutation and PARP Inhibitors

  2013cites this paper
• The Impact of Chromosomal Aberrations on the Regulation of Kallikrein 6 Expression in Serous Ovarian Carcinoma

  2013cites this paper
• PARP and PARP Inhibitor Therapeutics

  2013cites this paper
• Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations

  2013cites this paper
• Base excision repair of radiation-induced DNA damage in mammalian cells

  2013cites this paper
• Improved survival for BRCA2‐associated serous ovarian cancer compared with both BRCA‐negative and BRCA1‐associated serous ovarian cancer

  2012cites this paper
• The Role of Luteal Phase Fallopian Tube Epithelium in High-grade Ovarian Serous Carcinoma

  2012cites this paper
• Targeting PARP-1 in Breast Cancer: Th e Paradigm of a DNA Repair-based Th erapeutic Strategy

  2012cites this paper
• BRCAness: finding the Achilles heel in ovarian cancer.

  2012cites this paper
• E2F3b over‐expression in ovarian carcinomas and in BRCA1 Haploinsufficient fallopian tube epithelium

  2012cites this paper
• [PARP inhibitors and breast cancer: update and perspectives].

  2012cites this paper
• The changing view of high-grade serous ovarian cancer.

  2012cites this paper
• Chapter 4 – The role of PARP in DNA repair and its therapeutic exploitation

  2012cites this paper
• MiR‐182 overexpression in tumourigenesis of high‐grade serous ovarian carcinoma

  2012cites this paper
• Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.

  2012cites this paper
• Defective homologous recombination in human cancers.

  2012cites this paper
• Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation

  2012cites this paper
• High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.

  2012cites this paper
• BRCA GENE AND MOLECULAR DEFECTS IN BRCANESS The phenotypic traits of BRCAness are reflective of defective function of the BRCA pathway in the affected cancer cells

  2012cites this paper
• DNA repair dysregulation from cancer driver to therapeutic target

  2012cites this paper
• Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.

  2011cites this paper